InnoventricAnnounced the completion of a new round of $28.5 million in financing. This latest round of financing was led by RA Capital Management.European Innovation Council (EIC) Fund、BRM Group, JG Private Equity, and Mivtach Shamir Holdings followed with investments. To dateInnoventricHave completed over 41$00 million in financing."We are delighted to support Innoventric as it seeks to transform TR treatment methods.The robust results from their first-in-human trial in Europe suggest that their device holds significant potential for treatment."We are impressed by Innoventric's technology and leadership and believe their solutions have the potential to significantly reshape the future of TR care."---Anurag Kondapalli RA Capital ManagementExecutive Evaluation
"Our mission is to revolutionize tricuspid regurgitation care through minimally invasive therapies, significantly improving patient outcomes."The strong support from investors, coupled with the progress we have made, underscores the necessity and tremendous potential of our approach to treating TR.”---Amir Danino CEO of InnoventricInnoventricGroundbreaking Treatment Method---TRILLIUM，Through ectopic, trans-cavalThe method replaces the function of the natural valve and resolves tricuspid regurgitation. MeanwhileTRILLIUMUnique Treatment Approach Overcomes Traditional Tricuspid Valve Limitations, Such as I Leakage and Detachment Risk。TRILLIUMAlready in EuropeSuccessfully completed the first human clinical trial, and conducted multiple additional implants, treating more than 40 patients to date.
TRILLIUMIt is a simple, safe, and reliable transcatheter tricuspid regurgitation solution.TRILLIUMBySuperior Vena Cava (SVC) and Inferior Vena Cava (IVC)A covered stent was placed in between, with multiple valves opened in the middle of the stent to ensureCavityThe blood in the veins can flow to the left atrium while preventing backflow.CavityVein。
InnoventricThe reason for not considering the same approach as the mainstream TTVR on the market, which directly replaces the tricuspid valve, is due to full consideration of the physiological structure of the left ventricle and left atrium.Replacing the tricuspid valve is much more complex than TAVR. The human tricuspid valve is not circular, and the 3D shape of the annulus varies from patient to patient, making fixation difficult. Additionally, during the cardiac cycle, the shapes of the chordae tendineae and papillary muscles change, a complexity that does not exist with the aortic valve.At the same timeInnoventricDiscovery of the Left AtriumBoth the vena cava and the aortic valve are tubular structures, and they are small in size (compared to the tricuspid annulus), making anchoring easier and surgical manipulation simpler.ThereforeInnoventricConsiderTricuspid ValveDue to the complexity of physiological structures, therefore not chosen inTricuspid ValveThe position is not replaced, but a valve to prevent reflux is added at another position to achieve the TTVR function.Based on the above ideas,TRILLIUMDesigned.
TRILLIUMExpected to achieve effects that traditional TTVR cannot realize:Suitable for Various Anatomical Structures
Prevent Postoperative Movement
Prevent leakage (leakage is the biggest problem with traditional TTVR, given the highly irregular nature of the tricuspid valve).
Immediately reduce venous pressure
No anesthesia required
Precise Positioning
Placement time should be controlled within 10 minutes.
InnoventricIt is an innovative Israeli company, Innoventric Ltd., which is dedicated to developing simple and complex transcatheter solutions that significantly improve the life expectancy and quality of life for patients with structural heart disease.
